Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04066725 · ClinicalTrials.gov registry record · Phase 2
Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma
A Phase 2 study, sponsored by University of Utah.
- Completed
- Registry status
- Phase 2
- Development phase
- 95
- Enrollment target
NCT04066725 is a Phase 2 study that has completed, run by University of Utah. The registered enrollment target is 95 participants.
The verdict
NCT04066725, a Phase 2 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 95 participants
- Enrollment target
Study Summary
This is a phase II placebo-controlled intervention trial assessing aspirin (ASA) as a UV protectant in patients at risk for melanoma.
Interventions
- DRUG Placebo oral tablet
- DRUG Aspirin 325mg
- DRUG Aspirin 81 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2019-07-25 |
| Est. Completion | 2021-03-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04066725
The ClinicalTrials.gov registry entry for NCT04066725 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo oral tablet is the first listed.
NCT04066725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04066725 about?
NCT04066725 is a clinical study titled "Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma". This is a phase II placebo-controlled intervention trial assessing aspirin (ASA) as a UV protectant in patients at risk for melanoma.
What is the current status of trial NCT04066725?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 95 participants. The study started on 2019-07-25. Estimated completion is 2021-03-19.
What interventions are being tested in trial NCT04066725?
The interventions under investigation include: Placebo oral tablet (DRUG), Aspirin 325mg (DRUG), Aspirin 81 mg (DRUG).
Who is sponsoring clinical trial NCT04066725?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.